{
    "clinical_study": {
        "@rank": "56925", 
        "arm_group": [
            {
                "arm_group_label": "Fentanyl 400 \u00b5g sublingual spray + naltrexone 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients received a single administration of 400 \u00b5g of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally."
            }, 
            {
                "arm_group_label": "Actiq\u00ae 400 \u00b5g transmucosally + naltrexone 50 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients received a single administration of 400 \u00b5g of Actiq\u00ae transmucosally + naltrexone hydrochloride 50 mg orally."
            }, 
            {
                "arm_group_label": "Fentanyl citrate injection 100 \u00b5g iv + naltrexone 50 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients received a single administration of 100 \u00b5g of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to compare the rate of absorption and bioavailability of\n      fentanyl 400 \u00b5g sublingual spray, Actiq\u00ae 400 \u00b5g transmucosally, and fentanyl citrate\n      injection 100 \u00b5g intravenously."
        }, 
        "brief_title": "Pharmacokinetic Study of Fentanyl 400 \u00b5g Sublingual Spray, Actiq\u00ae 400 \u00b5g Transmucosally, and Fentanyl Citrate Injection 100 \u00b5g Intravenously (iv)", 
        "completion_date": {
            "#text": "May 2007", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "This was a Phase I, single-dose, open-label, randomized, 3-period, 3-treatment cross over\n      study in which 21 healthy subjects received single doses of fentanyl 400 \u00b5g sublingual\n      spray, Actiq\u00ae 400 \u00b5g transmucosally, and fentanyl citrate injection 100 \u00b5g intravenously\n      following a 10-hour overnight fast.  There was a 7 day washout period between treatments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant, non-breast-feeding female between the ages of 18-55 inclusive.\n\n          -  Body Mass Index (BMI) between 18-30 kg/m^2, inclusive, and body weight of at least 60\n             kg (132 lbs).\n\n          -  Subject was healthy according to the medical history, laboratory results, and\n             physical examination.\n\n        Exclusion Criteria:\n\n          -  Had a presence or history of clinically significant cardiovascular, pulmonary,\n             hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,\n             neurologic, oncologic, or psychiatric disease or any other condition which, in the\n             opinion of the Investigator would jeopardize the safety of the subject or the\n             validity of the study results.\n\n          -  Had a clinically significant abnormal finding on the physical exam, medical history,\n             electrocardiogram (ECG), or clinical laboratory results at screening.\n\n          -  Had a significant history of hypersensitivity to opioid analgesics, fentanyl or any\n             related products, naltrexone, or severe hypersensitivity reactions (like angioedema)\n             to any drugs.\n\n          -  Had a significantly abnormal diet during the 4 weeks preceding the first dose of\n             study medication.\n\n          -  Had donated blood or plasma within 30 days prior to the first dose of study\n             medication or during the course of this study.\n\n          -  Had participated in another clinical trial within 30 days prior to the first dose of\n             study medication or during the course of this study.\n\n          -  Had used any over-the-counter (OTC) medication, including nutritional supplements,\n             within 7 days prior to the first dose of study medication or during the course of\n             this study.\n\n          -  Had used any prescription medication, except hormonal contraceptive or hormonal\n             replacement therapy, within 14 days prior to the first dose of study medication or\n             during the course of this study.\n\n          -  Had used enzyme altering drugs such as barbiturates, corticosteroids, phenothiazines,\n             cimetidine, carbamazepine, etc, within 30 days prior to the first dose of study\n             medication or during the course of this study.\n\n          -  Had used opioid analgesics within the last 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780233", 
            "org_study_id": "INS-06-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fentanyl 400 \u00b5g sublingual spray + naltrexone 50 mg", 
                "intervention_name": "Fentanyl 400 \u00b5g sublingual spray", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Actiq\u00ae 400 \u00b5g transmucosally + naltrexone 50 mg", 
                "description": "Actiq\u00ae 400 \u00b5g is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.", 
                "intervention_name": "Actiq\u00ae 400 \u00b5g transmucosally", 
                "intervention_type": "Drug", 
                "other_name": "fentanyl citrate"
            }, 
            {
                "arm_group_label": "Fentanyl citrate injection 100 \u00b5g iv + naltrexone 50 mg", 
                "intervention_name": "Fentanyl citrate injection 100 \u00b5g intravenously", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Fentanyl 400 \u00b5g sublingual spray + naltrexone 50 mg", 
                    "Actiq\u00ae 400 \u00b5g transmucosally + naltrexone 50 mg", 
                    "Fentanyl citrate injection 100 \u00b5g iv + naltrexone 50 mg"
                ], 
                "description": "Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.", 
                "intervention_name": "Naltrexone 50 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Naltrexone", 
                "Fentanyl"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78759"
                }, 
                "name": "CEDRA Clinical Research, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single-dose Crossover Study of Fentanyl Sublingual Spray 400 Mcg Versus Actiq\u00ae 400 Mcg Versus Fentanyl Citrate Injection (iv) 100 Mcg Under Fasted Conditions", 
        "overall_official": [
            {
                "affiliation": "INSYS Therapeutics Inc", 
                "last_name": "Neha Parikh", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "CEDRA Clinical Research", 
                "last_name": "Frederick A. Bieberdorf, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Time to reach the maximum drug concentration (Tmax) in plasma", 
            "safety_issue": "No", 
            "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum drug concentration (Cmax) in plasma", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time-0 to the time of the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time-0 extrapolated to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Percentage of AUCinf based on extrapolation (AUCextrap)", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Observed elimination rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Observed terminal elimination half-life (T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Time of the last measurable concentration of drug (Tlast) in plasma", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }, 
            {
                "measure": "Last quantifiable drug concentration (Clast) in plasma", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 minutes pre-dose to 36 hours post-dose"
            }
        ], 
        "source": "INSYS Therapeutics Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INSYS Therapeutics Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}